

# Conditional logistic regression and propensity score analysis

CMED6020 – Session 6

Eric Lau (ehylau@hku.hk)

School of Public Health  
The University of Hong Kong

1 Mar 2021

## Session 6 learning objectives

After this session, students should be able to

- Fit conditional logistic regression model to data from case control study
- Understand the assumptions of the propensity score method
- Interpret results from propensity score method

# Conditional logistic regression

# Case control study

- Comparison between case and controls who are at risk and have the same exposure distribution as the case
- Types of case control study
  - Matched case-control study
  - Nested case-control study
  - Risk set sampling
- Matching: balancing certain characteristics between groups to increase efficiency
- Types of matching
  - Individually matched (paired)
  - Frequency matched

# Analysis of matched data

- More coherent in the same stratum
  - Correlated in the same stratum / match set
- Unconditional analysis
  - Estimate the parameter  $\beta$  of primary interest
  - Need to specify the stratum-specific parameters  $\alpha$
  - Suitable for frequency matching and multiple controls
- Conditional analysis
  - Group matched individuals into strata and perform comparison within strata
  - Analogy: paired t-test
  - Needed for individual matching

# Conditional logistic regression

- Model incorporating the stratum-specific effect:
- $\text{logit}(p_{ij}) = \alpha_i + \beta_1 x_{1ij} + \dots$ 
  - for the  $j^{\text{th}}$  individual in match set  $i$
- $\alpha_i$  are nuisance parameters
- Conditional likelihood is used to ‘remove’ the nuisance parameters

$$\prod_{i=1}^I \frac{\exp(\cancel{\alpha_i} + \beta_1 x_{ij1} + \dots)}{\sum_{j=1}^{J_i} \exp(\cancel{\alpha_i} + \beta_1 x_{ij1} + \dots)}$$

- analogy: risk set in survival analysis

The life table (using 4-year time periods)

Period	$n$	$d$	$c$	$n'$	$p$	$q$	$S$
(years)	# at risk	# deaths	# censor	# at risk	Prob of death in period	Prob to survive period	Cumulative survival at end of period
0 – 4	45	14	0	45	0.31	0.69	0.69
4 – 8	31	8	2	30	0.27	0.73	0.51
8 – 12	21	4	5	18.5	0.22	0.78	0.40
12 – 16	12	2	3	10.5	0.19	0.81	0.32
16 – 20	7	0	7	3.5	0.00	1.00	0.32

# Conditional logistic regression in R

`clogit(formula, data, subset, ...)` (in package: survival)

- syntax similar to `glm`
- formula: need to specify the strata
  - `case.status ~ exposure + strata(matched.set)`
- data: specifies the data frame
- subset: specifies subset of the data

# Dataset - MERS and dromedary camel exposure

- saved in 'examplemers.csv'
- population: 100 persons from the general population at risk of MERS
- 1:1 case-control study matched by age, sex and residence
- outcome variable – MERS infection
- exposure of interest: dromedary camel exposure
- other associating factors
  - currently smoking
  - exposure to sheep





## Dataset - MERS and dromedary camel exposure

```
> mers <- read.csv("examplermers.csv")
```

```
> head(mers)
```

	id	strata	case	age	male	loc	dromedary	sheep	smoking
1	1	1	1	69	1	4	0	0	0
2	2	1	0	69	1	4	0	0	0
3	3	2	1	54	0	2	0	0	0
4	4	2	0	54	0	2	0	0	0
5	5	3	1	36	0	2	1	1	0
6	6	3	0	36	0	2	0	0	1

## Fitting a conditional logistic regression model

```
> clr.mers <- clogit(case ~ dromedary + sheep + smoking +  
  strata(strata), data=mers)
```

```
> summary(clr.mers)
```

Call:

```
coxph(formula = Surv(rep(1, 100L), case) ~ dromedary + sheep +  
  smoking + strata(strata), data = mers, method = "exact")
```

n= 100, number of events= 50

	coef	exp(coef)	se(coef)	z	Pr(> z )	
dromedary	2.2966	9.9403	0.8711	2.637	0.00838	**
sheep	-0.4022	0.6688	0.6075	-0.662	0.50791	
smoking	2.7015	14.9027	0.9007	2.999	0.00271	**

---

Signif. codes: 0 '\*\*\*' 0.001 '\*\*' 0.01 '\*' 0.05 '.' 0.1 ' ' 1

## Fitting a conditional logistic regression model (cont'd)

	<code>exp(coef)</code>	<code>exp(-coef)</code>	<code>lower .95</code>	<code>upper .95</code>
dromedary	9.9403	0.1006	1.8028	54.81
sheep	0.6688	1.4952	0.2033	2.20
smoking	14.9027	0.0671	2.5501	87.09

`Rsquare= 0.216` (max possible= 0.5 )

`Likelihood ratio test= 24.34` on 3 df, `p=2.118e-05`

`Wald test` = 11.28 on 3 df, `p=0.01029`

`Score (logrank) test = 19.15` on 3 df, `p=0.0002542`

- exposure to dromedary is significantly associated with MERS infection (OR=9.9, 95%CI = 1.8-54.8)
- also for smoking

# Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study

Cao-Lormeau et al, Lancet, 2016

## Summary

**Background** Between October, 2013, and April, 2014, French Polynesia experienced the largest Zika virus outbreak ever described at that time. During the same period, an increase in Guillain-Barré syndrome was reported, suggesting a possible association between Zika virus and Guillain-Barré syndrome. We aimed to assess the role of Zika virus and dengue virus infection in developing Guillain-Barré syndrome.

**Methods** In this case-control study, cases were patients with Guillain-Barré syndrome diagnosed at the Centre Hospitalier de Polynésie Française (Papeete, Tahiti, French Polynesia) during the outbreak period. Controls were age-matched, sex-matched, and residence-matched patients who presented at the hospital with a non-febrile illness (control group 1; n=98) and age-matched patients with acute Zika virus disease and no neurological symptoms (control group 2; n=70). Virological investigations included RT-PCR for Zika virus, immunofluorescent and seroneutralisation assays for Zika virus and dengue virus. We studied in patients with Guillain-Barré syndrome using both ELISA and combinatoria

2012 census). The association between Zika virus positive serology, dengue positive serology, and Guillain-Barré syndrome was analysed with exact conditional logistic regression. Because the humoral response elicited by acute Zika virus infection might trigger production of anti-dengue virus IgG related to past dengue infections, we adjusted the odds ratio (OR) describing the association between anti-dengue IgG and Guillain-Barré syndrome for the presence of anti-Zika virus IgG. All ORs are given with 95% CIs.

	Guillain-Barré syndrome* (n=42)	Control group 1 (n=98)	OR (95% CI)	OR† (95% CI)	Control group 2 (n=70)	OR (95% CI)	OR† (95% CI)
Zika virus IgM and/or IgG positivity	41 (98%)	35 (36%)	59.7 (10.4–+∞)	..	..	..	..
Positive Zika virus seroneutralisation	42 (100%)	54 (56%)	34.1 (5.8–+∞)	..	..	..	..
Dengue virus IgG positivity	40 (95%)	87 (89%)	2.0 (0.4–19.9)	1.0 (0.2–11.5)	58 (83%)	6.0 (0.8–269.5)	4.0 (0.5–184.7)

Data are n (%), unless otherwise shown. \*Tested samples for patients with Guillain-Barré syndrome are late samples (around 3 months after admission). †Adjusted for Zika virus IgG positivity. OR=odds ratio.

**Table 4:** Zika virus and dengue virus serological patterns associated with Guillain-Barré syndrome

# Propensity score analysis

# Propensity score analysis

- to analyze data from 'quasi experiment'
  - quasi experiment: little control on the allocation of treatment and associating factors
  - selection bias / group nonequivalence
    - treatment may tend to select patients with certain characteristics
    - patients with certain characteristics may select treatment
    - ⇒ patients across different treatments may not be comparable
- to balance observed characteristics across treatment
  - so that more accurate estimates of the treatment effect can be estimated
- allow analysis on factors associated with treatment assignment

## Propensity score analysis (cont'd)

- adjustment of confounders by regression analysis
  - a rule of thumb – observed 10 events per level of the predictors
  - otherwise under-powered
  - propensity score method has higher power and more robust especially when the number of observed events is small
  - estimate the conditional effect:  $E(Y_1 - Y_0 | X)$
- can estimate the population marginal effect
  - marginal effect:  $E(Y_1 - Y_0)$
  - marginal effect may differ from conditional effect with uneven distribution of  $X$

## Propensity score analysis – MI example

- saved in 'examplemi.csv'
- population: 400 men aged 40-70 admitted to hospital with suspected myocardial infarction
- outcome variable – 30-day mortality
- treatment: newer clot-busting drug vs standard therapy
- main confounding factors
  - age
  - pre-existing risk factor level (0-5, 5: highest risk)
  - admission severity score (0-10, 10: most severe)



## Dataset - MI example

```
> mi <- read.csv("examplemi.csv")
```

```
> mi[1:10,]
```

	age	male	risk	severity	trt	death
1	48	1	3	8	0	0
2	59	1	4	6	1	0
3	67	1	3	6	0	1
4	51	1	0	6	0	0
5	56	1	1	6	1	0
6	60	1	1	6	0	0
7	53	1	0	3	1	0
8	54	1	1	2	0	0
9	54	1	2	7	0	0
10	62	1	0	4	0	0

## Crude mortality - MI example

```
> with(mi, table(trt, death), 1)
```

```
      death
```

```
trt    0    1
```

```
  0 168  40
```

```
  1 162  30
```

```
> round(with(mi, prop.table(table(trt, death), 1)), 3)
```

```
      death
```

```
trt    0    1
```


```
  0 0.808 0.192
```

```
  1 0.844 0.156
```

- treatment: 15.6%, control (standard therapy): 19.2%
  - estimated treatment effect = 3.6%, 95% CI (-3.9%, 11.1%)
- confounders not adjusted

```
with(mi, t.test(death~trt))
```

# Patient characteristics - MI example




```
mi$trt <- as.factor(mi$trt)
```

```
ggplot(mi, aes(x=age, fill=trt)) +  
  geom_histogram(binwidth=1) +  
  facet_grid(trt ~ .)
```

- patients receiving the newer treatment tends to be older


## Patient characteristics - MI example



```
ggplot(mi, aes(x=risk, fill=trt)) +  
  geom_histogram(binwidth=1) +  
  facet_grid(trt ~ .)
```

- patients receiving the newer treatment tend to have higher risk

## Patient characteristics - MI example



- patients receiving the newer treatment slightly more severe

## Summary of patient characteristics

- those received the newer clot-busting drug are in general:
  - older
  - more pre-existing risk factors
  - slightly more severe
- these factors are highly associated with mortality

# Propensity score

- derive a “propensity score” for each case
- propensity score  $p_i$ 
  - the probability (propensity) of assigning to treatment for individual  $i$
  - depends on the covariates / factors
  - does not depend on the outcome
- rationale:
  - to compare individuals with similar propensity scores (treatment vs no treatment)
  - any difference in the outcome should then be due to the treatment effect only

# Propensity score analysis – key assumptions

- conditional independence / unconfoundedness
  - given the observable predictors  $X$ , potential outcomes  $Y$  are independent of treatment assignment  $T$
  - ⇒ treatment assignment only depends on observed characteristics
- common support / overlap condition
  - $P(T=1|X) < 1$  for some observed predictors  $X$ 
    - If  $P(T=1|X) = 1$ , all individuals with observed predictors  $X$  are treated and no ‘similar’ control can be found for comparison
  - to ensure sufficient sample size between treatment groups for comparison



# Deriving the propensity score

- estimate propensity score  $p_i$ 
  - logistic regression (predict treatment vs control)
    - $\text{logit}(p_i) = X_i\beta$
  - multinomial regression (several treatment groups)
  - other models can also be considered
    - e.g. classification trees, probit regression
  - predictors
    - excluding the outcome of the treatment
    - may include interaction terms to increase accuracy to predict treatment assignment
    - important to check if balance of characteristics across treatment groups is achieved
  - balancing patient characteristics more important than parsimony

# Deriving the propensity score – MI example

- fit a logistic regression to predict treatment assignment
  - propensity score: predicted probability of receiving clot-busting drug
  - predictors: age, risk factor score, admission severity score
  - interactions may also be considered if it improves accuracy or improve balance of characteristics across groups
  - outcome of the treatment should not be included as predictors

## Deriving the propensity score – MI example

- fit logistics regression model to predict treatment, without the final outcome of interest (death)


```
ps.model <- glm(trt ~ age + risk + severity, data=mi,  
               family=binomial)
```

```
mi$ps <- predict(ps.model, type='response')
```

```
> head(mi)
```

	age	male	risk	severity	trt	death	ps
1	48	1	3	8	0	0	0.5773106
2	59	1	4	6	1	0	0.6362960
3	67	1	3	6	0	1	0.6506088
4	51	1	0	6	0	0	0.4009893
5	56	1	1	6	1	0	0.4824049
6	60	1	1	6	0	0	0.5126509

# propensity score distribution by treatment



- common support in the range 0.2 – 0.8

# Propensity score methods


- Stratification by propensity score
  - e.g. stratified by quintiles of the propensity score
  - to remove most of the selection bias
  - treatment effect is estimated within each stratum
  - overall treatment effect can be estimated by (weighted) mean of the stratum-specific treatment effect

## Stratification by propensity score quintiles

```
ps.boundary <- quantile(mi$ps, 0:5/5)
> ps.boundary
      0%      20%      40%      60%      80%     100%
0.2014026 0.3458898 0.4271172 0.5255349 0.6054821 0.8082802
mi$psq <- cut(mi$ps, ps.boundary, right=F,
  include.lowest=T, label=1:5)
```

- the cut off points for the quintiles are 0.346, 0.427, 0.526, 0.605
- define the stratification according to the quintiles
- next step: is balance of characteristics across treatment groups achieved?

## Boxplot – age by PS strata




Age is more balanced across treatment type in each propensity score strata

```
ggplot(mi, aes(x=trt, y=age)) +  
  geom_boxplot(aes(fill=trt)) +  
  facet_grid(psq ~ .,  
    labeller=label_both) + coord_flip()
```

```
alternatively:  
with(mi, boxplot(age ~ trt*psq,  
  col=c("red", "yellow")))
```

## Boxplot – risk by PS strata




may also be used to  
evaluate factors of  
treatment assignment

```
ggplot(mi, aes(x=risk)) +  
  geom_histogram(binwidth=1,  
    fill='blue') + facet_grid(trt ~  
    psq, labeller=label_both)
```



# Boxplot – severity by PS strata



```
ggplot(mi, aes(x=severity)) +  
  geom_histogram(binwidth=1,  
    fill='blue') + facet_grid(trt ~  
    psq, labeller=label_both)
```

# Assessment of balance across treatment groups

- assuming continuous outcome for risk and severity
- t-statistics unadjusted and adjusted for PS strata (by linear regression)

	unadjusted	adjusted
Age	4.41	0.73
Risk	4.75	-0.16
Severity	3.84	0.15

```
For age:  
summary(lm(age~trt,  
data=mi))  
summary(lm(age~trt+psq,  
data=mi))
```

- all three factors are much more balanced in the PS strata
- may also assess balance by mean standardized difference

## MI mortality by PS strata - result

```
> mean.tp <- aggregate(death~trt+psq, data=mi, FUN=mean)
> count.tp <- aggregate(death~trt+psq, data=mi, FUN=length)
> cbind(mean.tp, count.tp$death)
```

	trt	psq	death	count.tp\$death
1	0	1	0.11111111	54
2	1	1	0.03846154	26
3	0	2	0.20833333	48
4	1	2	0.16666667	30
5	0	3	0.14893617	47
6	1	3	0.17142857	35
7	0	4	0.30769231	39
8	1	4	0.14634146	41
9	0	5	0.25000000	20
10	1	5	0.20000000	60

in general, mortality rates were lower  
for patients receiving clot-busting drug

## MI mortality by PS strata - result

```
> n.psq <- as.numeric(table(mi$psq))
```

```
> n.psq
```

```
[1] 80 78 82 80 80
```

```
> cbind(mean.tp, count.tp$death)
```

	trt	psq	death	count.tp\$death
1	0	1	0.11111111	54
2	1	1	0.03846154	26
3	0	2	0.20833333	48
4	1	2	0.16666667	30
5	0	3	0.14893617	47
6	1	3	0.17142857	35
7	0	4	0.30769231	39
8	1	4	0.14634146	41
9	0	5	0.25000000	20
10	1	5	0.20000000	60

overall treatment effect =  $[ 80 \cdot (0.04 - 0.11) + 78 \cdot (0.17 - 0.20) + 82 \cdot (0.17 - 0.15) + 80 \cdot (0.15 - 0.31) + 80 \cdot (0.20 - 0.25) ] / 400 = -0.0603$

```
sum((mean.tp$death[mean.tp$str==1]-
mean.tp$death[mean.tp$str==0])*n.psq)/sum(n.psq)
```

## MI mortality by PS strata - result

```
> var.tp <- aggregate(death~trt+psq, data=mi, FUN=var)
```

```
> cbind(var.tp, count.tp$death)
```

	trt	psq	death	count.tp\$death
1	0	1	0.10062893	54
2	1	1	0.03846154	26
3	0	2	0.16843972	48
4	1	2	0.14367816	30
5	0	3	0.12950971	47
6	1	3	0.14621849	35
7	0	4	0.21862348	39
8	1	4	0.12804878	41
9	0	5	0.19736842	20
10	1	5	0.16271186	60

variance of estimated treatment effect

$$= [ 80^2(0.10/54 + 0.04/26) + 78^2(0.17/48+0.14/30) + \dots ] / 400^2$$

$$= 0.00159$$

```
sum((var.tp$death/count.tp$death)*rep(n.p
sq, each=2)^2)/sum(n.psq)^2
```

95% CI = (-0.14, 0.02)

# Propensity score methods

- Propensity score matching
  - match each treated individual to 1 or n individuals from the control group
  - matching methods
    - nearest-neighbor matching
    - caliper matching
      - matched controls to cases with propensity score within a preset distance
    - Mahalanobis metric matching
      - standardized squared distance relative to variation
    - stratification is also a kind of matching (by range)
  - compare outcome in the 'case' vs 'control'
    - e.g. paired t-test, McNemar's test
    - unconditional or conditional analysis (on matched pairs/sets)

# Propensity score matching

`matchit(formula, data, method = "nearest", distance = "logit", ...)` (in package: MatchIt)

- **formula** syntax similar to glm
- **data**: indicates the data frame to be used
- **method**: specifies a matching method: "exact", "nearest" (nearest neighbor matching), "optimal", and "subclass" (subclassification)
- **distance**: specifies the method used to estimate the distance measure. The default is logistic regression, "logit"

## MI example – propensity score matching

```
> m.out <- matchit(trt ~ age + risk + severity, data = mi,  
  method = "subclass", subclass=20)  
  
> summary(m.out)
```

Summary of Balance for All Data:

	Means Treated	Means Control	Std. Mean Diff.	Var. Ratio	eCDF Mean	eCDF Max
distance	0.5215	0.4417	0.5506	1.3136	0.1616	0.2616
age	58.6354	54.9615	0.4449	0.9959	0.1185	0.2508
risk	1.9896	1.3125	0.4392	1.3872	0.1128	0.2224
severity	5.2760	4.4712	0.3732	1.1276	0.0732	0.1899

Summary of Balance Across Subclasses

	Means Treated	Means Control	Std. Mean Diff.	Var. Ratio	eCDF Mean	eCDF Max
distance	0.5215	0.5208	0.0047	1.0082	0.0070	0.0313
age	58.6354	58.0408	0.0720	1.0381	0.0331	0.1061
risk	1.9896	2.0797	-0.0584	0.9182	0.0168	0.0458
severity	5.2760	5.2614	0.0068	1.0380	0.0129	0.0385



## MI example – matched subclass

```
> matched.mi <- match.data(m.out)
```

```
> matched.mi[matched.mi$subclass==1,]
```

	age	male	risk	severity	trt	death	distance	weights	subclass
27	43	1	0	1	1	0	0.2132211	1.0000000	1
31	42	1	0	2	0	0	0.2308658	0.5416667	1
35	48	1	1	1	0	0	0.2739481	0.5416667	1
45	45	1	0	3	0	0	0.2728490	0.5416667	1
52	46	1	0	1	0	0	0.2288440	0.5416667	1
55	48	1	0	2	1	0	0.2646589	1.0000000	1
64	40	1	0	4	0	0	0.2691281	0.5416667	1
76	47	1	0	2	1	0	0.2588127	1.0000000	1
79	40	1	0	4	0	0	0.2691281	0.5416667	1
81	49	1	0	1	0	0	0.2452549	0.5416667	1

...

## MI example – propensity score matching

```
> matched.mi <- match.data(m.out)
```

Extract the matched dataset

```
> clr.mi <- clogit(death ~ trt + strata(subclass),  
  data=matched.mi)
```

```
➤ summary(clr.mi)
```

	coef	exp(coef)	se(coef)	z	Pr(> z )
trt1	-0.4275	0.6521	0.2857	-1.496	0.135

	exp(coef)	exp(-coef)	lower .95	upper .95
trt1	0.6521	1.533	0.3725	1.142

## Propensity score methods (cont'd)

- Propensity score (inverse probability) weighting

- to estimate  $E[Y_1 - Y_0]$
- observed outcome is actually conditioned on assigned treatment
  - ie, observed  $E[Y_1|T=1]$  and  $E[Y_0|T=0]$
- estimate  $E[Y_i]$  by  $E[Y_i \delta(T=i)/P(T=i)]$ ,  $i=0, 1$

- $\delta$ : indicator function

- treatment effect =  $\frac{1}{N} \left( \sum_{\text{trt}=1} \frac{Y_{1i}}{p_{1i}} - \sum_{\text{trt}=0} \frac{Y_{0i}}{1-p_{1i}} \right)$

- approximate variance for binary outcome:

$$\frac{1}{N^2} \left( \sum_{\text{trt}=1} \frac{1-p_{1i}}{p_{1i}} + \sum_{\text{trt}=0} \frac{p_{1i}}{1-p_{1i}} \right)$$

- estimated effect for clot-busting therapy = -0.065, 95% CI = (-0.163, 0.033)

Your turn:  
Try estimating the treatment  
effect by PS weighting method

## Adjustment by propensity score

- fit linear / logistic regression
- propensity score as the only predictor to predict outcome

```
> lr.ps <- glm(death~trt+ps, data=mi, family=binomial)
```

```
> summary(lr.ps)
```

Coefficients:

	Estimate	Std. Error	z value	Pr(> z )	
(Intercept)	-2.7162	0.5063	-5.364	8.12e-08	***
trt1	-0.4932	0.2838	-1.738	0.08220	.
ps	2.8135	1.0116	2.781	0.00541	**

## Propensity score methods (cont'd)

```
> exp(coef(lr.ps))
```

(Intercept)	trt1	ps
0.06612525	0.61067986	16.66896399

```
> exp(confint(lr.ps))
```

	2.5 %	97.5 %
(Intercept)	0.02368166	0.1733016
trt1	0.34705278	1.0591376
ps	2.35437201	125.5768623

OR for clot-busting drug = 0.611, 95% CI = (0.35, 1.06)

## Example – effectiveness of SARS treatment

- compare SARS fatality rate for patients treated with ribavirin, corticosteroids, or both

Characteristic	Hong Kong (n = 1743)							
	Neither Treatment	(%)	Ribavirin Only	(%)	Corticosteroids Only	(%)	Ribavirin and Corticosteroids	(%)
Men	379	(50.5)	85	(42.1)	23	(45.1)	286	(38.7)
Age ≤ 39 y	297	(39.5)	123	(60.9)	19	(37.3)	403	(54.5)
Age 40-49 y	124	(16.5)	36	(17.8)	6	(11.8)	172	(23.3)
Age 50-59 y	73	(9.7)	15	(7.4)	7	(13.7)	93	(12.6)
Age 60-69 y	70	(9.3)	14	(6.9)	8	(15.7)	30	(4.1)
Age > 69 y	187	(24.9)	14	(6.9)	11	(21.6)	41	(5.5)
Health care worker	120	(16.0)	72	(35.6)	7	(13.7)	205	(27.7)
With preexisting comorbid conditions	220	(29.3)	28	(13.9)	18	(35.3)	90	(12.2)
Data on comorbid conditions missing	2	(0.3)	0	(0.0)	0	(0.0)	0	(0.0)
Died	175	(23.3)	18	(8.9)	15	(29.4)	93	(12.6)

Lau et al, Am J Med, 2009

- patient characteristics not balanced across treatment groups
- patients receiving no treatment seem to have high fatality rate

## Example – effectiveness of SARS treatment

- propensity scores were estimated and used as weights for the fatality rate
- patient characteristics were found to be balanced across treatment groups after PS adjustment

Treatment	Hong Kong		
	Case Fatality Ratio <sup>a</sup> (%)	95% CI	<i>P</i> Value <sup>b</sup>
Neither ribavirin nor corticosteroids	15.4	(13.2-17.6)	—
Ribavirin	17.0	(6.2-27.8)	.77
Corticosteroids	18.9	(4.6-33.1)	.64
Both	19.2	(14.2-24.3)	.16

- controlled for patients characteristics, no evidence of lower fatality rate for patients receiving both ribavirin and corticosteroids

## Limitations - PS analysis

- assumption of unconfoundedness not testable
- cannot control for unobserved selection to treatment
  - reduce biases but cannot ensure significant biases remain
- need larger samples to achieve balance of patient characteristics (similar to randomized design)
- sufficient overlap of characteristics across treatment groups is needed for accurate estimation of treatment effect



## Summary - PS

- estimate treatment effect / group differences, controlled for observed confounders
- estimate propensity score for stratification, matching, weighting or adjustment
- most useful when
  - few events of interest are observed relative to the (confounding) factors needed to be considered
  - interested in factors associated with treatment assignment

# Review

- We have discussed how to carry out conditional logistic regression for matched case control study
- We have discussed how to use propensity score method to handle confounding

## Further reading

- Khandker SR, Koolwal GB, Samad HA. *Handbook on Impact Evaluation: Quantitative Methods and Practices*. Washington: The World Bank. 2010.
- Vittinghoff, E, et al. *Regression methods in biostatistics*. Springer, 2005